Pfizer Stock Leads 3 AI Healthcare Picks Worth A Closer Look

Simply Wall St.07-10

Transformative AI in healthcare sits at the crossroads of powerful themes investors are watching today: pressure to improve efficiency, closer scrutiny on costs, and fast progress in data driven tools...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650405903?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","is_english":true,"pubTime":"2026-07-10 07:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650405903","market":"us","top_or_hot":-1,"title":"Pfizer Stock Leads 3 AI Healthcare Picks Worth A Closer Look","media":"Simply Wall St.","content":"<div>\n<p>Transformative AI in healthcare sits at the crossroads of powerful themes investors are watching today: pressure to improve efficiency, closer scrutiny on costs, and fast progress in data driven tools...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bfly/butterfly-network/news/pfizer-stock-leads-3-ai-healthcare-picks-worth-a-closer-look\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Stock Leads 3 AI Healthcare Picks Worth A Closer Look</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Stock Leads 3 AI Healthcare Picks Worth A Closer Look\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-10 07:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-bfly/butterfly-network/news/pfizer-stock-leads-3-ai-healthcare-picks-worth-a-closer-look><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Transformative AI in healthcare sits at the crossroads of powerful themes investors are watching today: pressure to improve efficiency, closer scrutiny on costs, and fast progress in data driven tools...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bfly/butterfly-network/news/pfizer-stock-leads-3-ai-healthcare-picks-worth-a-closer-look\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999003800.SGD","symbol_name":"Nikko AM Global Dividend Equity Acc SGD-H","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bfly/butterfly-network/news/pfizer-stock-leads-3-ai-healthcare-picks-worth-a-closer-look","article_id":"2650405903","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bfly/butterfly-network/news/pfizer-stock-leads-3-ai-healthcare-picks-worth-a-closer-look","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2650405903","pubTimestamp":1783640324,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Transformative AI in healthcare sits at the crossroads of powerful themes investors are watching today: pressure to improve efficiency, closer scrutiny on costs, and fast progress in data driven tools. While central banks and bond markets react to inflation and energy shocks, AI healthcare stocks tap into a different story, one built around diagnostics, personalized treatment and faster research. This article highlights 3 of the best stocks from our Transformative AI Healthcare Stocks...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4592":"伊斯兰概念","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","BK4082":"医疗保健设备","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4588":"碎股","HEAL":"Global X HealthTech ETF","SG9999001176.USD":"United Global Healthcare Acc USD","PFE":"辉瑞","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4007":"制药","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999002232.USD":"Allianz Global High Payout USD","BK4581":"高盛持仓","BK4599":"减肥药","ARKG":"ARK Genomic Revolution ETF","BK4121":"生命科学工具和服务","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BFLY":"Butterfly Network Inc","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","TEM":"Tempus AI","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4613":"AI应用软件","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4611":"AI医疗","TEMT":"2倍做多TEM ETF-Tradr","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","OZEM":"Roundhill GLP-1 & Weight Loss ETF","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU2596442595.SGD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (SGDHDG) INC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H"},"translate_title":"辉瑞股票领先 3 家值得仔细关注的人工智能医疗保健精选","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HEAL":0.6,"PFE":1.95,"TEMT":0.6,"TEM":1.92,"OZEM":0.6,"ARKG":0.6,"BFLY":1.93},"content_text":"Transformative AI in healthcare sits at the crossroads of powerful themes investors are watching today: pressure to improve efficiency, closer scrutiny on costs, and fast progress in data driven tools. While central banks and bond markets react to inflation and energy shocks, AI healthcare stocks tap into a different story, one built around diagnostics, personalized treatment and faster research. This article highlights 3 of the best stocks from our Transformative AI Healthcare Stocks screener. The screener is designed to help you focus on companies aiming to use AI to improve accuracy, access and affordability in global health systems. AdvertisementButterfly Network (BFLY) Overview: Butterfly Network is a medical technology company that makes handheld ultrasound devices and AI powered software so clinicians can perform whole body imaging at the bedside using a single probe connected to a phone, tablet, or hospital computer. Its platform also extends into bladder scanning, veterinary applications, education tools, and enterprise software that links devices, workflows, and departments. Operations: Butterfly Network generates around US$102.9m in revenue from providing an AI enhanced personal ultrasound solution, with about US$81.8m coming from the United States and US$21.2m from international markets. Market Cap: US$1.9b Butterfly Network gives investors exposure to handheld ultrasound powered by its ultrasound on chip technology and AI software such as Compass AI, which aims to make imaging more accessible and consistent across hospitals and clinics. Recent agreements that include upfront and potential milestone payments, along with guidance pointing to triple digit million annual revenue, indicate the business is pursuing multiple ways to monetize its technology. At the same time, Butterfly is still reporting losses, has a high P/S multiple, relies on higher risk external borrowing, and has seen insider share sales. Together, these factors point to elevated risk. For investors who can tolerate volatility, the combination of AI, medical devices, and licensing potential makes this company a closely watched name. Butterfly Network sits at the intersection of AI imaging excitement and real funding risk, so before you decide how it fits into your portfolio, review the 1 key reward and 2 important warning signs (1 is major!) NYSE:BFLY P/S Ratio as at Jul 2026 Pfizer (PFE) Overview: Pfizer is a global biopharmaceutical company that discovers, develops, manufactures and sells a wide range of prescription medicines and vaccines, covering areas such as cardiovascular disease, migraine, inflammation, rare diseases, oncology, biosimilars and sterile injectables. Operations: Pfizer generates about US$61.9b in revenue from its Global Biopharmaceuticals Business, supported by a Segment Adjustment of roughly US$1.4b. Market Cap: US$137.1b Pfizer provides exposure to a broad portfolio of established drugs and vaccines, along with a sizeable pipeline in obesity and oncology, areas where new therapies and label expansions could influence its earnings mix over time. The stock trades on a modest P/E, carries a high dividend yield around 7% and appears heavily discounted on some cash flow estimates, yet faces pressure from patent expirations, earnings declines and a balance sheet that leans on external funding. For investors interested in AI supported drug discovery, obesity treatments and oncology, while keeping an eye on payout and leverage risks, Pfizer combines income potential with pipeline execution risk and may warrant closer examination. Pfizer’s high dividend yield and modest P/E may be masking a deeper story in its drug portfolio and AI supported pipeline, so consider both perspectives through the 1 key reward and 4 important warning signs (3 are major!) NYSE:PFE P/E Ratio as at Jul 2026 Tempus AI (TEM) Overview: Tempus AI is a healthcare technology company that runs a data rich platform combining genomic and other lab diagnostics with clinical records and AI tools, so doctors and drug developers can make more precise decisions in cancer care and other conditions. Its products range from next generation sequencing tests and pharmacogenomic assays through to software like Lens and Next, which help life sciences customers analyze de identified patient data and design more targeted clinical trials. Operations: Tempus AI generates about US$1.4b in revenue from its Medical Labs & Research activities, all from the United States. Market Cap: US$10.3b Tempus AI gives investors exposure to one of the deepest healthcare data pools in the market, with tens of millions of de identified records feeding AI models that power both diagnostics for hospitals and high margin data and application sales to large pharmaceutical companies. The company is attracting blue chip partners, such as Gilead and Bristol Myers Squibb, and recent FDA decisions around its xT CDx assay and ECG AF model support its credibility in regulated settings. However, the stock still carries funding risk, ongoing losses, and a P/S that looks expensive compared with peers. For investors interested in where AI and precision medicine intersect, the balance between this growing data moat and the unresolved profitability profile is a key consideration. Tempus AI’s growing data moat could be masking where the real inflection sits in its story, so weigh the upside and funding risk through the 2 key rewards and 2 important warning signs NasdaqGS:TEM Earnings & Revenue Growth as at Jul 2026 The three stocks in this article are just a starting sample, and the full Transformative Artificial intelligence (AI) Healthcare Stocks screener on Simply Wall St surfaced 37 more companies with equally compelling AI in healthcare narratives through the Transformative Artificial intelligence (AI) Healthcare Stocks screener. Identify and analyze the specific catalysts that matter to you, from AI driven diagnostics and personalized medicine to hospital efficiency and remote monitoring, so you can focus on the highest conviction opportunities that best fit your own approach. Take Control of Your Investment Journey  If Tempus AI or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen.\n            Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.\n            Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.\n            By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.\n         Seeking Fresh Alternatives Beyond Healthcare? Markets move fast and tomorrow’s breakout ideas often start flying under the radar for now, before the crowd catches on. Scan these fresh stock shortlists and get in early.  Spot cash rich companies that aim to ride future upswings by screening a curated list of solid balance sheet and fundamentals (47 results) that is ready for the next leg of momentum. Zero in on income opportunities by reviewing a hand picked 9 dividend fortresses that could keep paying while other payouts are dropping or stalling. Track the backbone of AI rollouts by checking a focused 52 AI infrastructure stocks that is positioned to benefit as data demand builds and capacity tightens.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650405903","isCrawlerRequest":true}